A pill to treat obesity caused liver injury in ... still cost hundreds of dollars per month. Pfizer had already stopped testing of a twice-daily version of danuglipron in late 2023 after more ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing ... in late 2023 that it would abandon a twice-daily version of danuglipron that had ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing ... in late 2023 that it would abandon a twice-daily version of danuglipron that had ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company ... Pfizer previously discontinued a twice-daily version of the pill in December 2023 after patients ...

Morgan Stanley Research re-evaluated the global market for obesity ... setback for Pfizer's danuglipron, either. The company scrapped development of its twice-daily weight-loss pill in 2023 ...